Daily Stock Analysis, INSM, Insmed Inc, priceseries

Insmed Inc. Daily Stock Analysis
Stock Information
Open
19.40
Close
20.28
High
20.30
Low
19.40
Previous Close
19.21
Daily Price Gain
1.07
YTD High
33.13
YTD High Date
Apr 9, 2019
YTD Low
12.85
YTD Low Date
Jan 2, 2019
YTD Price Change
6.31
YTD Gain
45.17%
52 Week High
33.13
52 Week High Date
Apr 9, 2019
52 Week Low
11.31
52 Week Low Date
Dec 24, 2018
52 Week Price Change
3.01
52 Week Gain
17.43%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 17. 2017
17.23
May 3. 2017
18.18
12 Trading Days
5.54%
Link
LONG
Jun 19. 2017
15.97
Jun 30. 2017
17.21
9 Trading Days
7.74%
Link
LONG
Nov 2. 2017
27.92
Nov 17. 2017
30.35
11 Trading Days
8.69%
Link
LONG
Aug 2. 2018
28.08
Aug 3. 2018
29.83
1 Trading Days
6.23%
Link
LONG
Jan 4. 2019
14.85
Feb 21. 2019
25.28
32 Trading Days
70.25%
Link
LONG
Mar 29. 2019
29.07
Apr 17. 2019
30.61
13 Trading Days
5.30%
Link
Company Information
Stock Symbol
INSM
Exchange
NasdaqGS
Company URL
http://www.insmed.com
Company Phone
908-977-9900
CEO
Will Lewis
Headquarters
New Jersey
Business Address
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER, NJ 08807
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001104506
About

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.

Description

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.